It is a snapshot as of now. They don note future catalysts which will affect their valuation:
Future Material Catalysts:
■ ACAD announcements, particularly: DAYBUE sales results + ROW launch
■ Remaining study outcomes + NEU's progression &/or licensing of NNZ-2591
■ Clinical development of NNZ-2591 in Rett or Fragile X syndrome by ACAD
■ News flow around competing therapeutics for Rett or other indications, noting that
the nearest competing drug to DAYBUE, Anavex's blarcamesine 2-73 recently
failed to meet its study endpoints in paediatric Rett patients.
Neuren Media and Analyst Coverage, page-750
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.73 |
Change
-0.280(1.33%) |
Mkt cap ! $2.647B | |||
| Open | High | Low | Value | Volume |
| $20.87 | $21.19 | $20.70 | $6.213M | 297.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5414 | $20.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.79 | 335 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.73 |
Change
-0.280 ( 1.22 %) |
||||
| Open | High | Low | Volume | ||
| $20.99 | $21.19 | $20.69 | 94423 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| NEU (ASX) Chart |